Synonyms: LY-3090106 | LY3090106
Compound class:
Antibody
Comment: Tibulizumab (LY3090106) is an investigational bispecific monoclonal antibody. It is a humanized antibody that simultaneously targets IL-17A and BAFF (TNFSF13B; CD257), that was produced by Eli Lilly as a potential therapeutic for IL-17-driven autoimmune diseases. Peptide sequences for tibulizumab (accessed from IMGT) are 100% matches with SEQ IDs 1 and 2 from patent WO2013158577A1, entitled 'Anti-baff-anti-il-17 bispecific antibodies' [1]. Tibulizumab neutralises IL-17 and BAFF bioactivities in vitro and in vivo [1].
|
Classification | |
Compound class | Antibody |
International Nonproprietary Names | |
INN number | INN |
10656 | tibulizumab |
Synonyms |
LY-3090106 | LY3090106 |
Database Links | |
Specialist databases | |
IMGT/mAb-DB | 776 |
Other databases | |
GtoPdb PubChem SID | 384403631 |
Search PubMed clinical trials | tibulizumab |
Search PubMed titles | tibulizumab |
Search PubMed titles/abstracts | tibulizumab |